Cargando…

Unveiling the Potential of Liquid Biopsy in HER2-Positive Breast Cancer Management

SIMPLE SUMMARY: Breast cancer (BC) is the most prevailing cancer in women worldwide. Amongst the different BC subtypes, human epidermal growth factor receptor 2 (HER2)-positive tumours are characterised by an overexpression of the HER2 membrane receptor. Nowadays, HER2-status assessment relies on im...

Descripción completa

Detalles Bibliográficos
Autores principales:	Godoy-Ortiz, Ana, Alba-Bernal, Alfonso, Pascual, Javier, Comino-Méndez, Iñaki, Alba, Emilio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833720/ https://www.ncbi.nlm.nih.gov/pubmed/35158855 http://dx.doi.org/10.3390/cancers14030587

Ejemplares similares

Challenges and achievements of liquid biopsy technologies employed in early breast cancer
por: Alba-Bernal, Alfonso, et al.
Publicado: (2020)

Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications
por: Godoy-Ortiz, Ana, et al.
Publicado: (2019)

Evaluation of Liquid Biopsy in Patients with HER2-Positive Breast Cancer
por: Huai, Jianguo, et al.
Publicado: (2021)

Development of a Novel NGS Methodology for Ultrasensitive Circulating Tumor DNA Detection as a Tool for Early-Stage Breast Cancer Diagnosis
por: Jiménez-Rodríguez, Begoña, et al.
Publicado: (2022)

Liquid biopsy for HER2-positive breast cancer brain metastasis: the role of the cerebrospinal fluid
por: De Mattos-Arruda, Leticia
Publicado: (2017)

Breast and Gut Microbiota Action Mechanisms in Breast Cancer Pathogenesis and Treatment
por: Laborda-Illanes, Aurora, et al.
Publicado: (2020)

Analysis of the Cost-Effectiveness of Liquid Biopsy to Determine Treatment Change in Patients with Her2-Positive Advanced Breast Cancer in Colombia
por: Sánchez-Calderón, Diana, et al.
Publicado: (2020)

Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer
por: Allegretti, Matteo, et al.
Publicado: (2021)

Liquid Biopsy and Tissue Biopsy Comparison with Digital PCR and IHC/FISH for HER2 Amplification Detection in Breast Cancer Patients
por: Xie, Suhong, et al.
Publicado: (2022)

Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors
por: Chica-Parrado, María Rosario, et al.
Publicado: (2020)

Efficacy control of therapy using circulating epithelial tumor cells (CETC) as “Liquid Biopsy”: trastuzumab in HER2/neu-positive breast carcinoma
por: Pachmann, Katharina, et al.
Publicado: (2011)

Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer
por: Shen, Lin
Publicado: (2018)

Liquid Biopsy in Breast Cancer
por: Banys-Paluchowski, Maggie, et al.
Publicado: (2020)

Donor liquid biopsy and outcomes in kidney transplantation
por: Anfaiha-Sanchez, Miriam, et al.
Publicado: (2022)

Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue
por: Vollbrecht, Claudia, et al.
Publicado: (2022)

Electrochemical Cellulase-Linked ELASA for Rapid Liquid Biopsy Testing of Serum HER-2/neu
por: Díaz-Fernández, Ana, et al.
Publicado: (2023)

Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2019)

Diving into the Pleural Fluid: Liquid Biopsy for Metastatic Malignant Pleural Effusions
por: Sorolla, Maria Alba, et al.
Publicado: (2021)

Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy
por: Magbanua, Mark Jesus M., et al.
Publicado: (2022)

The Diversity of Liquid Biopsies and Their Potential in Breast Cancer Management
por: Keup, Corinna, et al.
Publicado: (2023)

Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy
por: Jung, Seung-Hyun, et al.
Publicado: (2023)

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2019)

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
por: Pascual, Tomás, et al.
Publicado: (2019)

Liquid biopsy in metastatic breast cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019)

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
por: Brasó-Maristany, Fara, et al.
Publicado: (2020)

Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib
por: Shishido, Stephanie N., et al.
Publicado: (2022)

The potential for liquid biopsies in the precision medical treatment of breast cancer
por: Forte, Victoria A., et al.
Publicado: (2016)

Potential utility of miRNAs for liquid biopsy in breast cancer
por: Liu, Xiangrong, et al.
Publicado: (2022)

Is there a role for immunotherapy in HER2-positive breast cancer?
por: Holgado, Esther, et al.
Publicado: (2018)

Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval
por: Ciruelos, Eva, et al.
Publicado: (2019)

Unveiling New Molecular Factors Useful for Detection of Pelvic Inflammatory Disease due to Chlamydia trachomatis Infection
por: Rodriguez-Cerdeira, Carmen, et al.
Publicado: (2012)

Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer
por: Hergueta-Redondo, Marta, et al.
Publicado: (2016)

Immunological Landscape of HER-2 Positive Breast Cancer
por: Moragon, Santiago, et al.
Publicado: (2022)

Her2-Positive and Microsatellite Instability Status in Gastric Cancer—Clinicopathological Implications
por: Bermúdez, Ana, et al.
Publicado: (2021)

HER2 gene assessment in liquid biopsy of gastric and esophagogastric junction cancer patients qualified for surgery
por: Grenda, Anna, et al.
Publicado: (2020)

Liquid biopsy based HER2 amplification status in gastric cancer patients indicates clinical response
por: Klein-Scory, Susanne, et al.
Publicado: (2023)

Liquid biopsy and multi-analyte testing guided treatment of HER2 positive periampullary adenocarcinoma with durable complete response after trastuzumab based therapy
por: Nagarkar, Rajnish, et al.
Publicado: (2020)

Liquid Biopsy Prevents Inaccurate Her2 Status Determination by in situ Hybridization in a Patient with Invasive Ductal Adenocarcinoma of the Breast: Case Report
por: Tzeng, Yen-Dun Tony, et al.
Publicado: (2017)

Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer
por: Gaibar, Maria, et al.
Publicado: (2020)

HER2/positive and HER2/low in inflammatory breast cancer recurrence
por: Movchan, Oleksii Volodimirovich, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_48ulaemdhu5dkqvqo70irgvl6c